Shigeki Ohtake

10PUBLICATIONS
47CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 14, 2026
ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

|Jun 18, 2026
Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

|Jun 11, 2026
Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

|Jul 05, 2024
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.

Itaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta

|Mar 29, 2023
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.

Yasuhito Nannya, Magnus Tobiasson, Shinya Sato

|Sep 13, 2021
Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Isamu Sugiura, Noriko Doki, Tomoko Hata

Pageof 2

Frequent Collaborators

5 joint publications

Itaru Matsumura

5 joint publications

Hitoshi Kiyoi

4 joint publications

Yukio Kobayashi

4 joint publications

Emiko Sakaida